4.4 Article

Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers

期刊

CEPHALALGIA
卷 32, 期 2, 页码 140-149

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/0333102411431333

关键词

PACAP38; dilatation; middle; meningeal; artery; headache

资金

  1. Lundbeck Foundation as part of the Lundbeck Foundation Centre for Neurovascular Signalling (LUCENS)
  2. Danish Agency of Science and Innovation (FIST)
  3. Allergan Inc
  4. AstraZeneca Pharmaceuticals LP
  5. Boehringer Ingelheim
  6. Eli Lilly
  7. GlaxoSmithKline
  8. Janssen Pharmaceutical Products
  9. Lundbeck
  10. Merck
  11. Pfizer

向作者/读者索取更多资源

Aim: To explore a possible relationship between vasodilatation and delayed headache we examined the effect of pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) on the middle meningeal artery (MMA) and middle cerebral artery (MCA) using high resolution magnetic resonance angiography (MRA). Methods: In a double-blind, randomized, placebo-controlled study 14 healthy volunteers were scanned repeatedly after infusion (20 min) of 10 pmol/kg/min PACAP38 or placebo. In addition, four participants were scanned following subcutaneous sumatriptan (6 mg). Results: We found significant dilatation of the MMA (p = 0.00001), but not of the MCA (p = 0.50) after PACAP38. There was no change after placebo (p > 0.40). Vasodilatation (range 16-23%) lasted more than 5 h. Sumatriptan selectively contracted the MMA by 12.3% (p = 0.043). Conclusion: PACAP38-induced headache is associated with prolonged dilatation of the MMA but not of the MCA. Sumatriptan relieves headache in parallel with contraction of the MMA but not of the MCA.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据